Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection

Journal of Cystic Fibrosis

Volumn 15, Issue 5, 2016, Pages 634-640

  Elborn, J Stuart ^a   Flume, Patrick A ^b   Cohen, Fredric ^c   Loutit, Jeffery ^d   VanDevanter, Donald R ^e  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c Future Therapies   (United States)

^d Medicines Company   (United States)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotics; Cystic fibrosis; Fluoroquinolone; Inhalation solution; Levofloxacin; Pseudomonas

Indexed keywords

AZITHROMYCIN; LEVOFLOXACIN; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; COUGHING; CRACKLE; CYSTIC FIBROSIS; DECREASED APPETITE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPNEA; EXERCISE TOLERANCE; FATIGUE; FEMALE; FEVER; FORCED EXPIRATORY VOLUME; HEMOPTYSIS; HUMAN; LUNG CONGESTION; LUNG FUNCTION TEST; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OPEN STUDY; OUTCOME ASSESSMENT; PLANTAR FASCIITIS; PSEUDOMONAS INFECTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SINUS HEADACHE; SPUTUM ANALYSIS; SPUTUM VISCOSITY; TREATMENT DURATION; TREATMENT INDICATION; WEIGHT REDUCTION; AEROSOL; DOSE RESPONSE; DRUG EFFECTS; DRUG MONITORING; INHALATIONAL DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; MICROBIOLOGY; PROCEDURES; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADULT; AEROSOLS; ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HUMANS; LEVOFLOXACIN; MALE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS; TOBRAMYCIN; TREATMENT OUTCOME;

EID: 84959193393     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2016.01.005     Document Type: Article

References (19)

1. [1] Emerson, J., Rosenfeld, M., McNamara, S., Ramsey, B., Gibson, R.L., Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 34 (2002), 91–100.
2. [2] Courtney, J.M., Bradley, J., McCaughan, J., O'Connor, T.M., Shortt, C., Bredin, C.P., et al. Predictors of mortality in adults with cystic fibrosis. Pediatr Pulmonol 42 (2007), 525–532.
3. [3] Konstan, M.W., Morgan, W.J., Butler, S.M., Pasta, D.J., Craib, M.L., Silva, S.J., et al. Scientific Advisory Group and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 151 (2007), 134–139 (e1).
4. [4] Döring, G., Flume, P., Heijerman, H., Elborn, J.S., Consensus Study Group, Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros 11 (2012), 461–479.
5. [5] Mogayzel, P.J. Jr., Naureckas, E.T., Robinson, K.A., Brady, C., Guill, M., Lahiri, T., et al. Cystic Fibrosis Foundation Pulmonary Clinical Practice Guidelines Committee. Cystic Fibrosis Foundation pulmonary guideline. pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection. Ann Am Thorac Soc 11 (2014), 1640–1650.
6. [6] Wagener, J.S., Rasouliyan, L., VanDevanter, D.R., Pasta, D.J., Regelmann, W.E., Morgan, W.J., et al. Investigators and coordinators of the epidemiologic study of cystic fibrosis. Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 48 (2013), 666–673.
7. [7] Jalal, S., Ciofu, O., Hoiby, N., Gotoh, N., Wretlind, B., Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother 44 (2000), 710–712.
8. [8] Tiddens, H.A., Bos, A.C., Mouton, J.W., Devadason, S., Janssens, H.M., Inhaled antibiotics: dry or wet?. Eur Respir J 44 (2014), 1308–1318.
9. [9] Geller, D.E., Flume, P.A., Staab, D., Fischer, R., Loutit, J.S., DJ, Conrad, et al. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med 183 (2011), 1510–1516.
10. [10] Stuart Elborn, J., Geller, D.E., Conrad, D., Aaron, S.D., Smyth, A.R., Fischer, R., et al. A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients. J Cyst Fibros 14 (2015), 507–514.
11. [11] Hankinson, J.L., Odencrantz, J.R., Fedan, K.B., Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 159 (1999), 179–187.
12. [12] Fuchs, H.J., Borowitz, D.S., Christiansen, D.H., Morris, E.M., Nash, M.L., Ramsey, B.W., et al. Pulmozyme Study Group. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 331 (1994), 637–642.
13. [13] Goss, C.H., Quittner, A.L., Patient-reported outcomes in cystic fibrosis. Proc Am Thorac Soc 4 (2007), 378–386.
14. [14] Quittner, A.L., Buu, A., Messer, M.A., Modi, A.C., Watrous, M., Development and validation of the Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. Chest 128 (2005), 2347–2354.
15. 1 changes among CF patients treated with inhaled antibiotics. J Cyst Fibros, 13(Suppl. 2), 2014, S6.
16. [16] Prince, A.S., Biofilms, antimicrobial resistance, and airway infection. N Engl J Med 347 (2002), 1110–1111.
17. [17] Assael, B.M., Pressler, T., Bilton, D., Fayon, M., Fischer, R., Chiron, R., et al. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial. J Cyst Fibros 12 (2013), 130–140.
18. [18] VanDevanter, D.R., Ballmann, M., Flume, P.A., Applying clinical outcome variables to appropriate aerosolized antibiotics for the treatment of patients with cystic fibrosis. Respir Med 105:Suppl. 2 (2011), S18–S23.
19. [19] Heltshe, S.L., Goss, C.H., Thompson, V., Sagel, S.D., Sanders, D.B., Marshall, B.C., et al. Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis. Thorax, 2015 [Epub ahead of print].